Success story of Aurobindo Pharma

In the period between 1988-89, the company only manufactured penicillin. They have since then expanded into antibiotics, anti-allergic, antiretrovirals, cardiovascular, central nervous system and gastroenterological categories.

In 2018, an Indian pharmacy became the second-largest generic pharmaceutical company in the world’s toughest market, the United States of America. We are talking about an Indian pharma company - Aurobindo Pharma. Not only did this company rival global giant Mylan it also gave severe competition to the world’s largest generic drug manufacturer -  Teva. Their marketing partners are AstraZeneca and Pfizer. The company’s founder. Ramprasad Reddy was one of the few drug manufactures that were invited to speak at the United Nations in 2006.

The journey of Aurobindo Pharma and its founder Ramprasad Reddy is truly inspiring. After his postgraduation in Commerce from Venkateshwara University, he along with friend Nityananda Reddy started trading. Nityananda Reddy with his education in Chemistry and work experience at Tini Pharma helped Ramprasad a lot. The small chemical traders soon turned their venture into a multinational pharmacy company worth billions of dollars. 

The company was founded in 1986 in Andra Pradesh. It was later converted into a Public Limited Company in 1992. In the period between 1988-89, the company only manufactured penicillin. They have since then expanded into antibiotics, anti-allergic, antiretrovirals, cardiovascular, central nervous system and gastroenterological categories. In 2014 for $41 million, Aurobindo purchased Actavis’s operation in seven European countries. In 2017, they acquired Portugal’s Generis for a whopping €135 million. They also acquired four biosimilar products from Swiss-based TL Biopharmaceuticals AG.

They are the largest manufacturer of Ampicillin and Cloxacillin in India. In 2018, 90% of the company’s revenue came from exports. Today, 70% of its revenue comes from exports that occur in 125 countries. Currently, an estimated 14% comes from generic injectables and oncology injectables. For the former Aurobindo has an estimated $400 million and for the latter $95 million. In FY21, generic injectables and the ophthalmic section alone reported Rs 9.3 billion in revenues. This was 5.9% of their overall revenue. 

Aurobindo Pharma and its founder Ramprasad Reddy’s tale is an inspiration to many. Coming from a humble background he has made for himself a fortune. Reddy, despite his language deficiencies, truly holds power in any negotiation. He has a steadfast decision making prowess and a discipline of keeping consistent prices. These traits have helped Reddy transform its small venture into a global giant in pharmaceuticals. 

Tags : #AurobindoPharma #RamprasadReddy #NityanandaReddy #AstraZeneca #Pfizer #multinationalpharmacy #pharmaceuticals #success #medicircle #smitakumar

About the Author

Priyal Shah

Priyal Shah is a graduate of Media from Mithibai College, Mumbai. She is a writer, researcher and avid reader.

Related Stories

Loading Please wait...


Trending Now

China Doctors Remove Live Worms from Woman’s Eyes HealthCare December 11, 2023
Immunity Boosting Measures for Optimal Health during WinterDecember 11, 2023
How to Save Gaza’ Catastrophic For HealthCareDecember 11, 2023
Broccoli Important For Our Health December 11, 2023
Seminar on RERA: Concerns in Real Estate heldDecember 09, 2023
Commonwealth youth leaders want action, not just rhetoric at COP28December 09, 2023
South India’s biggest Gaushala, Satyam Shivam Sundaram Gau Nivas to conduct Annakut Celebrations on Sunday on the eve of its 23rd AnniversaryDecember 08, 2023
Center for Diagnostics and Telemedicine Introduces Groundbreaking Service – Preliminary Clinical and Technical Testing for Medical SoftwareDecember 08, 2023
FTCCI to hold a Seminar on RERA: Concerns in Real EstateDecember 08, 2023
Adoption of Public Health Strategies and Early Detection Key for Cancer Mitigation: ExpertsDecember 08, 2023
Are online spaces safe for women?December 08, 2023
Prescribing Equality: Tackling Gender Disparities in India's Healthcare LeadershipDecember 07, 2023
Digitalizing Health: Generative AI's Impact Amplified by AWS Cloud in IndiaDecember 07, 2023
Eyes on the Future: Dr. Agarwal's Group Channels Rs 100 Crore for Cutting-edge Eye Hospitals Across KeralaDecember 06, 2023
Organ Transplant Scandal: Apollo Hospital Faces Government InquiryDecember 06, 2023
Breaking Barriers in Cancer Treatment: Max Healthcare's CAR-T Therapy PartnershipDecember 06, 2023
Exploring the Link Between Covid-19 Vaccination and Sudden Cardiac Arrests: ICMR StudyNovember 22, 2023
Powering the Future: China's Biodegradable Wireless System for Bioelectronic InnovationNovember 22, 2023
IMS BHU Pioneers Advanced Cardiac Care: Unveiling Cutting-Edge Technologies for Precise DiagnosisNovember 18, 2023
Inito's $6 Million Boost: Transforming Women's Health with AI-Backed Fertility MonitoringNovember 18, 2023